Health · 22 views
Another Win for Novel Drug, This Time in EGFR-Mutated Lung Cancer
(MedPage Today) -- A first-in-class bispecific antibody-drug conjugate (ADC) nearly doubled progression-free survival (PFS) compared with chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who…
Summary
(MedPage Today) -- A first-in-class bispecific antibody-drug conjugate (ADC) nearly doubled progression-free survival (PFS) compared with chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who progressed on third
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- The invisible global health workforce: Why nurses matter more than everContinue reading
- AI measurements of heart scans more strongly linked to patient survival than clinician measurementsContinue reading
- Novel Therapy Lands Speedy Approval for Wart-Like Airway DiseaseContinue reading
- Study Strengthens Case for Stent-Free PCI in De Novo Coronary LesionsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow